Axa S.A. Ironwood Pharmaceuticals Inc Transaction History

Axa S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$5.58 - $8.61 $18,179 - $28,051	-3,258 Reduced 10.37%	28,168 $183,000
Q1 2024 May 15, 2024	SELL	$8.32 - $15.45 $627,469 - $1.17 Million	-75,417 Reduced 70.59%	31,426 $273,000
Q4 2023 Jul 16, 2024	BUY	$8.79 - $11.51 $662,915 - $868,049	75,417 Added 239.98%	106,843 $1.22 Million
Q4 2023 Feb 14, 2024	BUY	$8.79 - $11.51 $703,577 - $921,294	80,043 Added 298.67%	106,843 $1.22 Million
Q3 2023 Nov 14, 2023	SELL	$8.25 - $11.35 $41,250 - $56,750	-5,000 Reduced 15.72%	26,800 $258,000
Q2 2023 Aug 14, 2023	BUY	$10.1 - $11.6 $99,990 - $114,840	9,900 Added 45.21%	31,800 $338,000
Q1 2023 May 15, 2023	BUY	$10.37 - $12.56 $227,102 - $275,064	21,900 New	21,900 $230,000
Q4 2021 Feb 14, 2022	SELL	$10.86 - $13.95 $840,564 - $1.08 Million	-77,400 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$11.92 - $13.92 $4.24 Million - $4.95 Million	-355,500 Reduced 82.12%	77,400 $1.01 Million
Q2 2021 Aug 13, 2021	BUY	$10.16 - $13.11 $4.4 Million - $5.68 Million	432,900 New	432,900 $5.57 Million

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $541M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.